Description
Paclimedak Concentrate for Infusions 6 mg/ml. 5 ml. (30 mg.) №1
Ingredients:
- Each ml contains 6 mg of Paclitaxel.
Dosage:
The recommended dosage of Paclimedak concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated.
Indications:
Paclimedak is indicated for the treatment of various cancers including ovarian, breast, lung, and pancreatic cancer.
Contraindications:
Do not use Paclimedak if you have a history of severe hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor EL.
Directions:
Paclimedak is administered intravenously by a healthcare professional in a hospital setting.
Scientific Evidence:
- Paclimedak has shown significant efficacy in various clinical trials for the treatment of solid tumors.
- Studies have demonstrated its ability to inhibit microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.
Additional Information:
- Paclimedak is a widely used chemotherapy drug that has demonstrated effectiveness in improving overall survival rates and quality of life in cancer patients.
- Common side effects include neutropenia, neuropathy, and myalgia.
- Pharmacological action involves stabilizing microtubules within the cell, disrupting the normal process of cell division and leading to cell death.
- Compared to similar drugs, Paclimedak has shown comparable efficacy with a more favorable side effect profile in some patient populations.
- Its use in combination therapies has shown promising results in improving treatment outcomes.
